Nuzenio

Rethinking Placebo

Rethinking Placebo news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 4 latest news signals 2 publisher sources 100/100 entity strength

Latest news

FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms - psychiatrictimes.compsychiatrictimes.com · Wed, 05 Aug 2026 20:45:21 GMTCentanafadine in ADHD: Clinical Significance of the First Triple Reuptake Inhibitor for ADHD - psychiatrictimes.compsychiatrictimes.com · Mon, 03 Aug 2026 18:23:02 GMTExpectation, Alliance, and Outcome: Rethinking Placebo in Psychiatric Practice - psychiatrictimes.compsychiatrictimes.com · Fri, 31 Jul 2026 07:00:00 GMTPlacebo effect forces Korea biotechs to rethink late-stage trial design - CHOSUNBIZ - ChosunbizChosunbiz · Tue, 28 Jul 2026 07:00:00 GMT

Timeline

Wed, 05 Aug 2026 20:45:21 GMTFDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms - psychiatrictimes.com
Mon, 03 Aug 2026 18:23:02 GMTCentanafadine in ADHD: Clinical Significance of the First Triple Reuptake Inhibitor for ADHD - psychiatrictimes.com
Fri, 31 Jul 2026 07:00:00 GMTExpectation, Alliance, and Outcome: Rethinking Placebo in Psychiatric Practice - psychiatrictimes.com
Tue, 28 Jul 2026 07:00:00 GMTPlacebo effect forces Korea biotechs to rethink late-stage trial design - CHOSUNBIZ - Chosunbiz

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Rethinking Placebo.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

2 distinct publisher/source names are currently connected to this entity page.